Applied Clinical Trials
TTC
TTC estimates that nearly $1.5 billion of US clinical grant spending should be covered as part of standard of care treatment (SOC) by third parties for their patients' participation in clinical trials.
SOC payment in oncology trials has been a common industry practice for a number of years. Sponsor pharmaceutical companies realize that the practice can be extended to other therapeutic areas as well. Additionally, large number of states specifically require that SOC procedures in clinical trials be covered by third party payers.
Clinical sites are accustomed to billing insurance claims for their patients in general. A survey of 512 investigator sites in the United States on their current third party payers billing practices found that two thirds of sites regularly bill third party payers for their patients participating in clinical trials. When broken out by therapeutic area, billing is regularly done for oncology trials (84% of sites), dropping to 30% of sites participating in digestive system trials.
The most mentioned reason by sites for not billing third party payers is simply that the sponsor did not ask them to.
—TTC (for more information, please contact help@ttc-llc.com)
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.